Adverse effects and safety of etirinotecan pegol, a novel topoisomerase inhibitor, in cancer treatment: A systematic review

Mohammad Samare-Najaf; Ali Samareh; Navid Jamali; Ali Abbasi; Cain C.T. Clark; Majid J. Khorchani; Fatemeh Zal

doi:10.2174/1573394717666210202103502

Adverse effects and safety of etirinotecan pegol, a novel topoisomerase inhibitor, in cancer treatment: A systematic review

Mohammad Samare-Najaf, Ali Samareh, Navid Jamali, Ali Abbasi, Cain C.T. Clark, Majid J. Khorchani, Fatemeh Zal^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

1 Citation (SciVal)

Original language	English
Pages (from-to)	234-243
Number of pages	10
Journal	Current Cancer Therapy Reviews
Volume	17
Issue number	3
DOIs	https://doi.org/10.2174/1573394717666210202103502
Publication status	Published (VoR) - Aug 2021

Funding

This article was commissioned by the Shiraz University of Medical Sciences, Shiraz, Iran. The authors would like to thank Mrs. Soolmaz Safari for her assistance. Furthermore, the authors thank Mr. Alireza Iranmanesh, Managing Direc-tor of Pixonald Company, for designing figures.

Funders	Funder number
Shiraz University of Medical Sciences

Keywords

Cancer
Chemotherapy
Clinical trials
Drug safety
Topoisomerase inhibitors
Toxicology

Access to Document

10.2174/1573394717666210202103502

Cite this

@article{3bc8fe6fd25a41d0b8cc43073d5416fc,

title = "Adverse effects and safety of etirinotecan pegol, a novel topoisomerase inhibitor, in cancer treatment: A systematic review",

keywords = "Cancer, Chemotherapy, Clinical trials, Drug safety, Topoisomerase inhibitors, Toxicology",

author = "Mohammad Samare-Najaf and Ali Samareh and Navid Jamali and Ali Abbasi and Clark, {Cain C.T.} and Khorchani, {Majid J.} and Fatemeh Zal",

note = "Publisher Copyright: {\textcopyright} 2021 Bentham Science Publishers.",

year = "2021",

month = aug,

doi = "10.2174/1573394717666210202103502",

language = "English",

volume = "17",

pages = "234--243",

journal = "Current Cancer Therapy Reviews",

issn = "1573-3947",

publisher = "Bentham Science Publishers",

number = "3",

}

TY - JOUR

T1 - Adverse effects and safety of etirinotecan pegol, a novel topoisomerase inhibitor, in cancer treatment

T2 - A systematic review

AU - Samare-Najaf, Mohammad

AU - Samareh, Ali

AU - Jamali, Navid

AU - Abbasi, Ali

AU - Clark, Cain C.T.

AU - Khorchani, Majid J.

AU - Zal, Fatemeh

PY - 2021/8

Y1 - 2021/8

KW - Cancer

KW - Chemotherapy

KW - Clinical trials

KW - Drug safety

KW - Topoisomerase inhibitors

KW - Toxicology

UR - http://www.scopus.com/inward/record.url?scp=85115433284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115433284&partnerID=8YFLogxK

U2 - 10.2174/1573394717666210202103502

DO - 10.2174/1573394717666210202103502

M3 - Review article

AN - SCOPUS:85115433284

SN - 1573-3947

VL - 17

SP - 234

EP - 243

JO - Current Cancer Therapy Reviews

JF - Current Cancer Therapy Reviews

IS - 3

ER -

Adverse effects and safety of etirinotecan pegol, a novel topoisomerase inhibitor, in cancer treatment: A systematic review

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this